Indaba Capital Management, L.P. → Accelerate Diagnostics, Inc

Item 4 of the Schedule 13D is hereby supplemented as follows: On February 4, 2025, the Fund purchased approximately $12.4 million in aggregate principal amount of the Issuer's New Convertible Notes from the holder of such notes. As a result of the acquisition of additional principal amount of New Convertible Notes, the Fund now owns a majority of the outstanding New Convertible Notes. Because the Fund beneficially owns a majority of the outstanding principal amount of New Convertible Notes, the Fund will have the ability to control any decision under the Indenture or the Security Agreement with respect to the New Convertible Notes that requires approval of the holders of a majority of the outstanding principal amount of the New Convertible Notes. Decisions requiring approval of the holders a majority of the outstanding principal amount of New Convertible Notes under the Indenture and the other Note Documents (as defined in the Indenture) include, without limitation (i) waivers of certain defaults or events of default under the Indenture and their consequences; (ii) consent to certain supplemental indentures or amendments or supplements to the Notes Documents for the purpose of modifying the terms of the Indenture and the New Convertible Notes; (iii) the direction of the time, method and place of conducting any proceeding for any remedy available to the Trustee or exercising any trust or power conferred on the Trustee with respect to the New Convertible Notes; (iv) removal of the Trustee and nomination a successor trustee; or (v) removal of the Collateral Agent and appointment of a successor Collateral Agent with the Issuer's written consent. The foregoing description of the Indenture and the other Note Documents does not purport to be complete and is qualified in its entirety to the Indenture and the Security Agreement filed as Exhibits 99.5 and 99.6 to the Initial Schedule 13D.